| Systematic (IUPAC) name | |
|---|---|
| 4-amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)- 1,3,5-triazin-2(1H)-one |
|
| Clinical data | |
| Trade names | Dacogen |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a608009 |
| Pregnancy cat. | D |
| Legal status | ℞ Prescription only |
| Routes | Intravenous |
| Pharmacokinetic data | |
| Protein binding | <1% |
| Half-life | 30 minutes |
| Identifiers | |
| CAS number | 2353-33-5 |
| ATC code | L01BC08 |
| PubChem | CID 451668 |
| DrugBank | DB01262 |
| ChemSpider | 397844 |
| UNII | 776B62CQ27 |
| KEGG | D03665 |
| ChEBI | CHEBI:50131 |
| ChEMBL | CHEMBL66115 |
| Chemical data | |
| Formula | C8H12N4O4 |
| Mol. mass | 228.206 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Decitabine (trade name Dacogen), or 5-aza-2'-deoxycytidine, is a cytidine analog.
Contents |
It is a hypomethylating agent.[1][2] It hypomethylates DNA by inhibiting DNA methyltransferase.
It functions in a similar manner to azacitidine, although decitabine can only be incorporated into DNA strands while azacitidine can be incorporated into both DNA and RNA chains.
Decitabine is indicated for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups.
Piml, J.; Sorm, F.; Coll. Czech. Chem. Commun. 1964, 29, 2576.